Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preemptive HLADQA1*05 Genotyping for Infliximab in Chinese Crohn's Disease
NCT05813860Phase 4Not yet recruiting
- Sponsor
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Start
- Apr 2023
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
01
Overview
Phase 4, randomised trial of infliximab in Crohn's disease (2 arms), sponsored by The Sixth Affiliated Hospital of Sun Yat-Sen University. Primary endpoint: Clinical remission without corticosteroid use at 102 weeks. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05813860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05813860.